DIVA Laboratories Ltd (4153.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN TW0004153002
DIVA Laboratories Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 862.32 m TWD | 868.84 m TWD |
| Gross profit | 260.18 m TWD | 264.14 m TWD |
| Operating income | 102.57 m TWD | 109.36 m TWD |
| EBIT | 116.16 m TWD | 108.99 m TWD |
| Net income | 93.66 m TWD | 90.54 m TWD |
| Diluted EPS – continuing operations | 1.60 TWD | 1.54 TWD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
More stocks
- Company K Partners Limited (307930.KQ)
- UPEXI, INC. (UPXI)
- Cardiff Oncology, Inc. (CRDF)
- ALUX Co., Ltd. (475580.KQ)
- Nordwest Handel AG (NWX.F)
- SYNergy ScienTech Corp (6558.TW)
- Titanium Oyj (TITAN.HE)
- Lix Solution Co.Ltd (029480.KQ)
- Ffbw Inc (FFBW)
- Transat AT Inc (TRZ.TO)
- Empery Digital Inc. (EMPD)
- StoneBridge Ventures Inc. (330730.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.